Both studies underscore the capacity of TGF-β expanded γδ T cell’s anti-tumor efficacy in liquid tumors or general immunogenic cancers, and we now show similar results using an immune-cold OS cancer. This evidence concerns the gene TGFB1 and neoplasm.